Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management.

Shuchita Gupta
Einstein Institute for Heart and Vascular Health

Vincent M. Figueredo, M.D.
Thomas Jefferson University, FigueredoV@einstein.edu

Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/cardiologyfp
Part of the Cardiology Commons

Recommended Citation
https://jdc.jefferson.edu/cardiologyfp/49
Tachycardia Mediated Cardiomyopathy: Pathophysiology, Mechanisms, Clinical Features and Management

Shuchita Gupta¹, MD, and Vincent M. Figueredo MD¹,²

Einstein Institute for Heart and Vascular Health, Einstein Medical Center, Philadelphia, PA¹ and Jefferson Medical College, Philadelphia, PA²

Disclosures: no conflict of interest or funding sources for preparation of this manuscript.

Address correspondence to: Vincent M Figueredo, MD

Einstein Institute for Heart and Vascular Health
5501 Old York Road, 3rd Floor Levy Building
Philadelphia, PA 19141
TEL: 215-456-8991
FAX: 215-456-3533,
E-mail: figueredov@einstein.edu
ABSTRACT

Tachycardia mediated cardiomyopathy (TMC) is a reversible form of dilated cardiomyopathy that can occur with most supraventricular and ventricular arrhythmias. Despite the plethora of literature describing this entity in animal models, as well as humans, it remains poorly understood. Over the last decade, new etiologies of TMC, such as frequent premature ventricular complexes in normal hearts, have been identified. Recent advances in catheter-based ablation therapies, particularly for atrial fibrillation and ventricular arrhythmias, have added a new dimension to the treatment of this condition. This review describes the pathophysiology, proposed mechanisms, clinical features and management in various arrhythmic conditions.

KEY WORDS: tachycardia mediated cardiomyopathy, tachycardia-induced heart failure, tachyarrhythmias
INTRODUCTION

Incessant tachyarrhythmias can lead to ventricular dilation and systolic dysfunction with signs and symptoms of heart failure (HF). Tachycardia-induced HF was first described in 1913 in a patient with atrial fibrillation (1). Philips and Levine described the relationship between rapid atrial fibrillation and reversible heart failure in 1949 (2). Whipple and colleagues developed an experimental model of tachycardia-mediated cardiomyopathy (TMC) in 1962 (3). Fenelon and colleagues divided TMC into two types: 1. pure, where tachycardia is the sole mechanism of worsening of LV function; and 2. impure, where tachycardia worsens a pre-existing cardiomyopathy due to a different cause (4).

Over the last 3 decades, multiple papers have described this entity in both animal models and in humans. Despite the plethora of literature, TMC remains a poorly understood entity. This review describes the pathophysiology, clinical features and natural history of TMC.

PATHOPHYSIOLOGY AND PROPOSED MECHANISMS

SYSTOLIC FUNCTION: In animal models of pacing-induced HF, sustained atrial or ventricular pacing produce severe biventricular systolic dysfunction. This is characterized by increased ventricular filling pressures, decreased cardiac output and increased systemic vascular resistance, without a change in left ventricular (LV) mass (5,6,7). There is loss of intrinsic myocardial contractility with diminished contractile reserve. The marked dilation of ventricles is accompanied by lack of hypertrophy of the left ventricular wall. Microscopic alterations include myocyte loss, myocyte elongation, and effacement of the interface between the basement
membrane and sarcolemmal surface. The latter leads to decrease force transmission through the ventricular wall (8,9). Depletion of T-tubules occurs in failing ventricular myocytes with rapid pacing, with associated decreases in the density of L-type calcium channels and beta-adrenergic receptors in both surface and T-tubular sarcolemmata. This heterogeneous loss of T-tubules results in abnormal excitation-contraction coupling and may impair contractile efficiency by causing variability in time course of activation of cells (10).

DIASTOLIC FUNCTION: Tachycardia also affects diastolic function by causing incomplete relaxation whereby the myocardium remains in a constant activated state that can be described as a partial or diastolic contracture (11). Calcium extrusion from cardiomyocytes occurs mainly by the sarcolemmal sodium-calcium exchanger. In concert with the sarcoplasmic reticulum (SR), the exchanger restores cytosolic calcium to diastolic levels, thereby causing relaxation. With tachycardia, there is a disproportionate increase in SR calcium content, causing extrusion of calcium in a high calcium environment, which manifests as diastolic contracture (12).

HIGH ENERGY PHOSPHATES: TMC causes depletion of high energy stores in the myocardium due to increased metabolism from persistent tachycardia; this being a reversible process. Tissue adenosine triphosphate (ATP), as well as sodium-potassium ATPase, are significantly decreased in animals with pacing-induced HF (13, 14), while there is an increase in beta-oxidation enzymes and enzymes involved in the Krebs’ cycle (15). Selective endothelin-receptor blockade has been shown to attenuate progression of HF by reversing mitochondrial dysfunction (specifically by affecting levels of respiratory complexes V and III involved in the
Krebs’ cycle) in animal models of TMC, thus suggesting the role of endothelin activation in causing ventricular dysfunction (16).

MYOCARDIAL BLOOD FLOW: Chronic supraventricular tachycardia (SVT) in animals has also been shown to result in decreased myocardial blood flow, which normalizes after pacing is terminated (17,18). This may be due to marked elevation of LV end-diastolic pressure (19).

OXIDATIVE STRESS: Oxidative stress has been proposed as a mechanism contributing to TMC in patients with atrial fibrillation (AF). In AF, oxidative modification of ventricular myofibrillar proteins occurs due to peroxynitrite formation, leading to loss of fibrillar function, eventually causing contractile dysfunction (20,21). In an animal study of pacing-induced HF, antioxidant vitamins reduced myocardial oxidative stress, attenuated cardiac dysfunction and prevented myocardial beta-receptor down-regulation and sympathetic nerve terminal dysfunction (22).

ANGIOTENSIN CONVERTING ENZYME: Angiotensin-converting enzyme (ACE) polymorphisms have also been implicated in TMC. Patients with DD genotype (287 base pair deletion in intron 16 of the ACE gene) show exaggerated ACE production in response to any stimulus such as incessant tachycardia. The resultant increase in levels of angiotensin-II causes myocyte elongation, left ventricular enlargement and changes in wall stress (23, 24).

NEUROHORMONAL CHANGES: The neurohumoral changes seen in TMC are similar to those in other forms of HF and occur in response to a depressed cardiac output. Activation of the renin-
angiotensin-aldosterone axis occurs with elevated levels of angiotensin-II, atrial natriuretic peptide (ANP) and endothelin-1, causing abnormal sodium handling. In pacing-induced HF, changes in heart rate, atrial pressure and volume cause increased plasma ANP concentrations, which are attenuated by 1 week due to inability of the atria to be stretched further and because of depletion of atrial ANP concentrations (25, 26). As in other disease states, elevated levels of aldosterone may lead to myocardial fibrosis (27, 28).

BETA-ADRENERGIC RECEPTORS: There is blunted response to beta-adrenergic stimulation in TMC due to decreased expression of beta-receptors, alterations in beta-receptor transduction including decreased G stimulator protein density (Gs), increased G inhibitory protein density (Gi), and reduced adenylate cyclase activity (29,30,31).

MITRAL REGURGITATION: Similar to other forms of dilated cardiomyopathy, patients with TMC can develop mitral regurgitation (MR) due to mitral annular dilatation and separation of the leaflet hinge points, causing incomplete leaflet coaptation and valve incompetence (32). The saddle shaped mitral annulus in TMC dilates more in the septal-lateral than in the commissure-commissure dimension with flattening of the annulus and decreased contraction occurring in the lateral annulus (33). There is also lengthening of the mitral leaflets due to remodeling near the leaflet edges (34).

RIGHT VENTRICLE: The right ventricle (RV) responds somewhat differently to tachycardia. Unlike the LV where chamber dilation occurs without increase in mass, in the RV, both chamber and myocyte hypertrophy develop. These changes in RV myocardial geometry are associated
with persistently higher RV myocyte contractile function compared to LV myocytes in TMC (35).

**RECOVERY FROM TMC:** In animal studies, recovery from TMC is associated with a hypertrophic response of the left ventricle with persistent dilation despite normalization of systolic function (17). This has subsequently been confirmed in clinical studies (36). Diastolic dysfunction can persist even after normalization of systolic function (37). Myocardial blood flow returns to normal, but with decreased coronary flow reserve. Therefore, episodic increases in myocardial oxygen demand in post-supraventricular tachycardia hearts (e.g., with recurrence of tachycardia) can result in reduced myocardial blood flow and reduced LV function (17).

In a study comparing patients with TMC due to SVT with those with idiopathic dilated cardiomyopathy (DCMP), significant improvement in LV ejection fraction was noted in the former group with rate control. LV dimensions and mass and volume indices were smaller in the TMC group than DCMP group. A lower LV end-diastolic dimension was the only significant predictor of recovery in multivariable analysis (38).

In a recent study of 18 patients with TMC due to focal atrial tachycardia that had an improvement in ejection fraction within 3 months of radiofrequency ablation, subtle differences in LV structure and function were noted at 5 years, with larger LV dimensions, lower EF, decreased myocardial strain and twist rate and evidence of diffuse myocardial fibrosis on late gadolinium enhanced cardiac MRI, suggesting incomplete recovery (39).
TACHYCARDIA-MEDIATED ATRIAL CARDIOMYOPATHY (TMAC)

Atrial tachycardia and atrial fibrillation (AF) have been shown to cause contractile dysfunction of the atria. In addition, cardioversion of AF to sinus rhythm causes atrial mechanical dysfunction, the degree of which depends upon the duration of preceding AF (40, 41). Rapid atrial pacing affects both atrial systolic and diastolic function characterized by absent atrial booster pump function, increased atrial chamber stiffness, enhanced atrial conduit function, and atrial enlargement (42). Abnormalities in calcium handling and impaired systolic transient calcium currents due to downregulation or dysfunction of the L-type calcium channel and altered myofilament function (associated with abnormal myosin and myosin-associated protein phosphorylation) have been proposed as mechanisms of the atrial cardiomyopathy (43,44,45,46). Upregulation of the sodium-calcium exchanger worsens calcium depletion by causing its efflux from atrial cardiomyocytes of AF patients, thus contributing to the atrial contractile dysfunction post cardioversion. Unlike its ventricular counterpart, beta-adrenergic receptor desentization does not contribute to TMAC (47).

INCIDENCE AND PREDISPOSING FACTORS

The incidence of TCM is variable depending upon the type of tachycardia. In a study of 625 patients referred for radiofrequency ablation of tachyarrhythmias, TCM was found in 17 patients (2.7%) (48). The incidence for specific arrhythmias has been described as ranging from 10% in patients with focal atrial tachycardia (49), to 20-50% in patients with permanent junctional reciprocating tachycardia (PJRT) (50, 51) and 25% in patients with incessant atrial flutter (52). The incidence of TCM in atrial fibrillation and ventricular tachycardia has not been described adequately in literature. Younger patients, males, those with slower tachycardias, and incessant
tachycardias are more prone to develop TMC according to one study (49). Those with rapid paroxysmal tachycardias are more likely to be symptomatic and be diagnosed sooner than those with slower, but incessant tachycardias. In patients with atrial fibrillation (AF), the irregularity of R-R interval may itself predispose to cardiomyopathy and heart failure, apart from the effects of rapid heart rates (50).

DIAGNOSIS AND MANAGEMENT

There are no established diagnostic criteria for TMC. However, in a patient presenting with new onset LV dysfunction and a chronic or recurrent tachycardia with heart rate over 100 beats per minute, the diagnosis of TMC may be suggested by the following once ischemic cardiomyopathy is ruled out:

1. No other cause of non-ischemic cardiomyopathy found (eg. hypertension, alcohol or drug use, stress etc.)
2. Absence of LVH
3. Relatively normal LV dimensions (LV end-diastolic dimension< 5.5 cm)
4. Recovery of LV function after control of tachycardia (by rate control, cardioversion or radiofrequency ablation) within one to six months.
5. Rapid decline in LVEF following recurrence of tachycardia in a patient with recovered LV function after control of tachycardia previously.

In addition, there is evidence that the ratio of N-terminal-pro brain natriuretic peptide (NT-pro-BNP) concentration in patients with suspected TMC before and after control of tachycardia may help in distinguishing these patients from those with structural heart disease. In one study, the level of NT-pro-BNP was elevated in patients with SVT with depressed LV function and
declined after cardioversion within a week (51). Thus serial measurements of NT-pro-BNP may be useful in supportive diagnosis of TMC, though this requires further exploration.

Initial management of TMC comprises evidence-based treatment for HF with reduced LVEF, including angiotensin converting enzyme inhibitors and beta-blockers. Treatment of tachycardia involves control of ventricular response with rate-controlling drugs, use of anti-arrhythmic drugs, direct-current cardioversion or catheter ablation of the tachyarrhythmia.

TMC AND RECURRENT TACHYCARDIA

TMC usually resolves with treatment of tachycardia. The time course of improvement in LVEF is variable. However, recurrence of tachycardia can cause a precipitous decline in LVEF due to persistent ultrastructural changes. Nerheim et al (52) described a series of 24 patients with TMC out of which 5 had recurrent tachycardia causing marked decline in LVEF. Three of their patients died suddenly and unexpectedly. This suggests that patients may be at increased risk for sudden cardiac death following improvement of TMC, which could be due to persistent myocardial fibrosis as demonstrated on cardiac MR (39).

ARRHYTHMIAS ASSOCIATED WITH TMC

A list of tachyarrhythmias that have been associated with TMC is shown in Table 1. Both supraventricular and ventricular arrhythmias can cause TMC, as can sinus tachycardia, particularly in association with thyrotoxicosis. We present some common arrhythmias associated with TMC and salient features in their management.
ATRIAL FIBRILLATION (AF): AF is the most common sustained arrhythmia, encountered in 1.5% of the population (53). AF compromises LV systolic function through poor rate control (usually sustained ventricular rates above 120 beats per minute), irregularity of ventricular response, and loss of atrial systolic activity. Loss of atrioventricular (AV) synchrony is associated with impaired diastolic filling, reduced stroke volume, and elevated diastolic atrial pressure, resulting in an approximately 20% reduction in cardiac output (54). AF and HF thus form a vicious cycle whereby one worsens the other.

Although conversion of a patient back to sinus rhythm appears an attractive therapeutic goal, in both AFFIRM (AF Follow-Up Investigation of Rhythm Management) and RACE (Rate Control Versus Electrical Cardioversion for Persistent AF) trials, rhythm control strategy provided no benefit and actually showed a trend toward harm in the general population of patients compared with rate control (55, 56). This was due, at least in part, to toxicity of the anti-arrhythmic drugs, along with an inability to maintain SR in most patients. These trials, however, did not address the issue of TMC.

Although rate control was found to be superior to rhythm control in AFFIRM and RACE, subsequent analyses suggested a benefit of maintaining sinus rhythm, which was completely offset by the toxicity of anti-arrhythmic drugs (57,58). One technique of achieving sinus rhythm without anti-arrhythmic drugs would be curative catheter ablation. In most cases, paroxysmal AF is initiated by triggers located within pulmonary vein musculature. Circumferential ablation to isolate this musculature can eliminate paroxysmal AF in selected populations. Because of the problem of recurrent pulmonary vein connections, more than one
procedure is needed in approximately 30% of patients, and new technologies are being
developed to reduce this requirement (59). In a study of patients undergoing pulmonary vein
isolation, 18% had depressed LVEF (<50%). The mean LVEF improved significantly in these
patients following ablation, the improvement being more marked in those who achieved
successful AF control (Figure 1). Of note, the degree of AF control in these patients was similar
to that in patients with normal LV function, but they required more procedures (60).

The Pulmonary Vein Antrum Isolation versus AV Node Ablation with Bi-Ventricular Pacing for
Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure (PABA-CHF) study
was a multicenter, randomized, controlled trial comparing pulmonary vein isolation with
atrioventricular-node biventricular pacing in patients with symptomatic AF, NYHA class II or III
HF and LVEF ≤ 40% (61). Patients who underwent pulmonary vein isolation demonstrated
greater improvement in LVEF, six-minute walk distance and quality of life parameters at 6
months compared to the latter group. However, long term superiority of one strategy over the
other has not been established as this was a relatively short follow-up period.

Catheter ablation is now being explored as first line therapy in persistent AF. A recent
randomized, open label, blinded-endpoint clinical trial involving 52 patients with symptomatic
HF, persistent AF and LVEF ≤ 35%, compared catheter ablation with rate control (62). Catheter
ablation significantly improved peak oxygen consumption (VO2), Minnesota Living with Heart
Failure Questionnaire score and brain-natriuretic peptide (BNP) values at 12 months, with a
trend towards increase in LVEF and six-minute walk distance. In this study, 96% of patients in
the rate control group had adequate rate control at 12 months, and maintenance of SR was
achieved in 92% of patients in ablation group. This study suggests that rhythm control with successful ablation of AF may have an overall advantage over adequate rate control for physiologic improvement, though longer follow-up is necessary.

An extreme form of rate control strategy is atrioventricular (AV) nodal ablation with implantation of a permanent pacemaker, the “ablate and pace strategy”. This procedure’s use is reserved largely for older patients with significant co-morbidities. It does result in progression of paroxysmal AF to permanent AF in up to 32% of patients within 2 months. Also, continuous right ventricular pacing itself has deleterious effects on LV systolic function due to LV dyssynchrony (63). However, AV nodal ablation may be beneficial if simultaneous cardiac resynchronization therapy (CRT) is performed in patients meeting CRT criteria. In a systematic review of 3 studies, AV nodal ablation was associated with a substantial reduction in all-cause mortality and cardiovascular mortality, with improvements in New York Heart Association functional class when compared with medical therapy in AF patients receiving CRT (64).

TMC RELATED TO OTHER SUPRAVENTRICULAR ARRHYTHMIAS: TMC can develop with any form of frequent paroxysmal or incessant supraventricular tachycardia. Patients with chronic atrial flutter have been shown to develop TMC, which improves after radiofrequency ablation (65,66). In a study of 345 patients undergoing catheter ablation for focal atrial tachycardia, TMC was seen in 10% of cases (49). Patients with TMC were younger, more often male, had mostly incessant tachycardia, and had a longer tachycardia cycle length and slower ventricular rate compared to those who did not have TMC. Foci of atrial tachycardia were mostly found either in the atrial appendages or the pulmonary veins in patients with TMC.
Normalization of LVEF was seen in 97% of patients at a mean follow-up of 3 months. Cruz et al. (67) described TMC resulting from incessant tachycardia due to an accessory pathway with a long retrograde conduction time, which was reversible following surgical ablation of the accessory pathway. Children may develop TMC with ectopic atrial tachycardia or permanent junctional reciprocating tachycardia, which is reversible following radiofrequency ablation (68,69,70,71).

TMC RELATED TO VENTRICULAR ARRHYTHMIAS: Ventricular arrhythmias that can cause TMC include ventricular tachycardia (VT) in patients with structurally normal hearts and frequent, monomorphic premature ventricular contractions (PVC) (72). Multiple case reports and case series have described TMC in association with idiopathic right ventricular outflow tract VT (RVOT-VT) (73,74) and idiopathic left ventricular tachycardia (75), where the cardiomyopathy was reversible after successful radiofrequency ablation. In a study of 249 patients with idiopathic repetitive monomorphic PVCs and/or VT, 9% had TMC, and 29% of these were asymptomatic (76). All patients had improvement in LVEF following treatment with either anti-arrhythmics or radiofrequency ablation. The predictors for development of TMC identified were male gender, absence of symptoms, PVC burden of ≥16%, persistence of PVCs throughout the day, and the presence of repetitive monomorphic VT. In another study by the same group, late gadolinium enhancement on cardiac magnetic resonance imaging was seen in patients with TMC who did not recover their LV systolic function after treatment of the index VT (77). Late gadolinium enhancement on cardiac magnetic resonance imaging is indicative of scar, thus these patients probably did not have pure TMC.
PVCs have been detected in 1% of subjects on standard 12-lead electrocardiography and between 40 and 75% of subjects on 24 to 48 hour ambulatory electrocardiographic monitoring in the normal population (78). PVCs were thought to be benign. However, in the last decade, cardiomyopathy due to frequent PVCs in otherwise healthy hearts is now recognized. In the Atherosclerosis Risk in Communities (ARIC) study, association of frequent PVCs with HF incidence in a population-based cohort, free of HF and coronary heart disease at baseline, was studied (79). Over a follow-up period of 15 years, the incidence of HF in subjects with >1 PVC on a 2 minute electrocardiographic rhythm strip was significantly higher than in those with no PVCs (hazard ratio 1.71, after adjusting for variables including coronary artery disease) (Figure 2).

The concept of PVC-induced cardiomyopathy was described by Duffee et al. (80) who noted that pharmacological suppression of PVCs in patients with presumed idiopathic dilated cardiomyopathy improved LV systolic dysfunction. The frequency of PVCs appears to correlate with LV dysfunction. Frequent PVCs have been variably defined as >10,000 PVCs in 24 hours (81), >20,000 PVCs in 24 hours (82) or >24% of total heart beats (83). Approximately a third of patients with frequent PVCs develop cardiomyopathy. Two-thirds of PVCs arise from outflow tracts, particularly the RVOT, and one-third have various ventricular origins: free walls, LV fascicles, septum and papillary muscles.

Mechanisms postulated for PVC-induced TMC include a true rate-related cardiomyopathy due to higher average heart rates in patients with frequent PVCs with a short coupling interval, LV dyssynchrony during PVCs and chronic effects of extra-systolic potentiation leading to increases
in intracellular calcium and myocardial oxygen consumption (84). Ventricular dyssynchrony causes reduced global cardiac mechanical efficiency, asymmetrically increased wall thickness in the late-activated regions, altered myocardial blood flow, and local changes in myocardial protein expression, thus causing LV dilation and dysfunction in a manner similar to chronic RV pacing (85). Identified predictors of cardiomyopathy in patients with frequent PVCs include (besides PVC burden) wider PVCs, PVCs of epicardial origin (86), presence of interpolated PVCs (87) and presence of retrograde P waves (88). The threshold burden of PVCs associated with reduced LVEF may be lower for right as compared to left ventricular PVCs (89).

A therapeutic medical trial for 3 months or catheter ablation should be considered for patients with presumed PVC-induced cardiomyopathy. Beta-blockers, amiodarone and dofetilide can all suppress PVCs and can be safely used in patients with LV dysfunction (90,91,92). Catheter ablation has emerged as an increasing popular option for these patients as the safety and efficacy profiles of the procedure have improved. Several studies have documented an improvement in LVEF following PVC ablation in nearly all patients along with significant reductions in LV end-diastolic dimensions of between 2 and 8 mm, mitral regurgitation by 75%, and New York Heart Association functional class by nearly 1 class (93,94,95). Significant improvement in radial, circumferential, and longitudinal strain after catheter ablation in patients with frequent PVCs and preserved LVEF has also been shown (96). Short-term ablation success rates of between 70% and 90% have been reported (97,98). Early improvement in LVEF after ablation (>25% increase at 1 week) was shown to predict complete recovery of LV systolic function in one study (98).
TMC IN THYROTOXICOSIS: Approximately 6% of patients with thyrotoxicosis develop HF symptoms, but only 1% develop dilated cardiomyopathy with reduced LV systolic function. This can occur with sinus tachycardia or atrial fibrillation with a rapid ventricular response. HF resulting from thyrotoxicosis is due to a tachycardia-mediated mechanism leading to increased levels of cytosolic calcium during diastole with reduced ventricular contractility and diastolic dysfunction (99). Most patients recover their LV systolic function after control of tachycardia and achievement of a euthyroid state. Patients who develop TMC have lower levels of serum thyroxine than those who do not, which reflects a higher incidence of subclinical hyperthyroidism in these patients (100).

FUTURE DIRECTIONS
While there is an abundance of animal studies on TMC, studies in humans are remarkably limited. Future research needs to be directed towards studying the pathophysiology of this entity in human beings, with particular reference to predisposing factors. It is likely that genetic factors (such as ACE polymorphism which has already been described) will be found to play a significant role in the development of TMC. Emerging data suggest that the presence of fibrosis on cardiac MR imaging may identify patients with TMC who are less likely to recover their LV function. These patients may be at elevated risk of recurrence of TMC as well as sudden cardiac death, which is a hypothesis that needs further exploration. In addition, with reference to atrial fibrillation, it remains to be determined whether conversion to sinus rhythm with catheter ablation has long-term superiority over rate control strategy in certain patients with TMC.
CONCLUSIONS

TMC is a form of dilated cardiomyopathy which can be reversible with treatment of the underlying tachycardia. TMC patients who gain return of LV function do remain at an elevated risk for recurrence and for sudden cardiac death, hence long-term follow-up of these patients is necessary.
REFERENCES


43. Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile
44. Schotten U, Ausma J, Stellbrink C et al. Cellular mechanisms of depressed atrial
45. Wakili R, Yeh Y, Yan Qi X, Greiser M et al. Multiple Potential Molecular Contributors
to Atrial Hypocontractility Caused by Atrial Tachycardia Remodeling in Dogs. Circ Arrhythm
Electrophysiol. 2010; 3:530-541.
inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy by rapid atrial pacing
47. Schotten U, Greiser M, Benke D, Buerkel K et al. Atrial fibrillation-induced atrial
contractile dysfunction: a tachycardiomyopathy of a different sort. Cardiovascular Research
49. Medi C, Kalman JM, Haqqani H et al. Tachycardia-Mediated Cardiomyopathy
Secondary to Focal Atrial Tachycardia: Long-Term Outcome After Catheter Ablation. J Am Coll
50. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence
51. Nia AM, Gassanov N, Dahlem KM, et al. Diagnostic accuracy of NT-proBNP ratio
Cardiol. 2011;100(10):887-896.


84. Huizar JF, Kaszala K, Potfay J, Minisi AJ et al. Left Ventricular Systolic Dysfunction


92. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with


100. Siu CW, Yeung CY, Lau CP, Kung AW et al. Incidence, clinical characteristics and
outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93(4):483-487.
FIGURE LEGENDS

1. Improvement in left ventricular ejection fraction (LVEF) based on atrial fibrillation (AF) control with ablation in patients with low LVEF. Improvement in LVEF was greater in those patients with AF control after ablation than in those with recurrent AF (P< 0.01).


2. Multivariable adjusted cumulative heart failure events during follow up by the presence any VPCs (143 HF events among 739) vs. absence (1201 HF events among 12747) events in a 2-minute ECG strip among ARIC cohort participants free of heart failure and coronary heart disease at study baseline. (Wilcoxon test P<0.001). Model adjusted for age, gender, race, study center, education level, diabetes, systolic blood pressure, hypertension medication intake, LDL and HDL cholesterol, BMI, current smoking, former smoking, pack-years of smoking, amount of ethanol use, heart rate, serum K+, serum Mg++.

Reprinted with permission from: Agarwal SK, American Journal of Cardiology Volume 109, Issue 1, pages 105-109, January 2012.
Figure 1

Bar chart showing:
- AF Control Post Procedure: 14%
- AF Post Procedure: 6%
Figure 2

Cumulative % of Heart Failure vs. Follow up time in years.

- Blue line: NO PVCs
- Red dashed line: Any PVC
Table 1. Types of Arrhythmias Causing Tachycardia-Mediated Cardiomyopathy

Supraventricular
- Atrial fibrillation
- Atrial flutter
- Atrial tachycardia
- Permanent junctional reciprocating tachycardia
- AV nodal reentrant tachycardia
- AV reentrant tachycardia
- Inappropriate sinus tachycardia (rare cause)

Ventricular
- Right ventricular outflow tract ventricular tachycardia
- Fascicular tachycardia
- Bundle branch reentry ventricular tachycardia

Ectopy
- Premature ventricular complexes

Pacing
- Persistent rapid ventricular pacing
- High-rate atrial pacing

Other
- Thyrotoxicosis (sinus tachycardia or atrial fibrillation)